| Literature DB >> 33987168 |
Shancheng Yu1, Huan Zhang2, Shiya Zhang1, Mingli Zhong3, Haiming Fan1,2.
Abstract
Ferrite nanoparticles have been widely used in the biomedical field (such as magnetic targeting, magnetic resonance imaging, magnetic hyperthermia, etc.) due to their appealing magnetic properties. In tumor acidic microenvironment, ferrite nanoparticles show intrinsic peroxidase-like activities, which can catalyze the Fenton reaction of hydrogen peroxide (H 2 O 2) to produce highly toxic hydroxyl free radicals (•OH), causing the death of tumor cell. Recent progresses in this field have shown that the enzymatic activity of ferrite can be improved via converting external field energy such as alternating magnetic field and near-infrared laser into nanoscale heat to produce more •OH, enhancing the killing effect on tumor cells. On the other hand, combined with other nanomaterials or drugs for cascade reactions, the production of reactive oxygen species (ROS) can also be increased to obtain more efficient cancer therapy. In this review, we will discuss the current status and progress of the application of ferrite nanoparticles in ROS-mediated cancer therapy and try to provide new ideas for this area.Entities:
Keywords: cancer therapy; cascade reaction; external field; fenton reaction; ferrite nanoparticles; reactive oxygen species
Year: 2021 PMID: 33987168 PMCID: PMC8110829 DOI: 10.3389/fchem.2021.651053
Source DB: PubMed Journal: Front Chem ISSN: 2296-2646 Impact factor: 5.221
Scheme 1Schematic illustration of the ferrite nanoparticles-based ROS-mediated cancer therapy. Increasing generation of highly toxic ROS under the catalysis of ferrite nanoparticles can break the balance between the production and elimination of ROS based on these mechanisms: (1) intrinsic Fenton reaction catalytic activity of ferrite nanoparticles, (2) external field enhanced Fenton reaction, and (3) cascade reactions increased ROS.
Figure 1(A) Illustration of interactions of FeOx-MSNs and H2O2. Turnbull's blue stain of ZR75-30 cells after incubation with (B) MSNs and (C) FeOx-MSNs. (D) Fluorescence emission spectra of DCF in ZR75-30 cells after incubation with FeOx-MSNs and/or H2O2. Fluorescence images of ZR75-30 cells in the (E) control and (F) FeOx-MSN plus H2O2 groups. Reproduced, with permission, from Fu et al. (2015). Copyright 2015, Royal Society of Chemistry.
Figure 2(A) Schematic illustration for the structural effect of Fe3O4 nanoparticles on ROS generation for cancer cell killing. (B) Endocytosis percentage of three kinds of Fe3O4 nanoparticles. (C) Cell viability incubated with Fe3O4 (1 mg/ml) alone or Fe3O4 (25 μg/ml) plus H2O2 (0.625 μM). Statistical significance, *p < 0.05, **p < 0.01. Reproduced, with permission, from Fu et al. (2017). Copyright 2017, Elsevier.
Figure 3(A) Illustration for cytotoxic effect of SnFe2O4 nanocrystals on cancer cells. (B) Fluorescent images of test cells. (C) Corresponding quantitative results obtained using MTT. *Statistical significance indicated by P < 0.05. Reproduced, with permission, from Lee et al. (2017). Copyright 2016, American Chemical Society.
Figure 4(A) Schematic illustration for Fe2O3@DMSA promoted ROS-induced tumoricidal autophagy. (B) Zeta potential of Fe2O3@DMSA and Fe2O3@APTS. (C,D) Cellular uptake of Fe2O3@DMSA and Fe2O3@APTS. (E) ROS production of SK-Hep-1 cells exposed to Fe2O3@DMSA or Fe2O3@APTS. (F) Photographs of tumors. Statistical significance, *p < 0.05, **p < 0.01, and ***p < 0.001 compared with control. #p < 0.05,p < 0.01, and p < 0.001 between the indicated groups. Reproduced, with permission, from Xie et al. (2020). Copyright 2020, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figure 5(A) Fabrication of DOX–ICG@Fe/FeO–PPP nanocapsules. (B) Volume change of tumor in different treatments. (C) Synergism schematic of Fenton reaction of Fe/FeO NCs with photothermal conversion (ICG). **p < 0.01, ***p < 0.001. Reproduced, with permission, from Wang et al. (2019c). Copyright 2019, Nature Publishing Group.
Figure 6(A) Schematic illustration for roles of ROS on PEI-MNPs elicited responses in cancer cells. (B,C) PEI-MNPs induced overproduction of ROS, triggering the activation of NF-κB and TGF-β pathways. (D) Western blotting experiments of the cancer cells treated with PEI-MNPs. *P < 0.05;**P < 0.01;***P < 0.005 vs controls. Reproduced, with permission, from Man et al. (2020). Copyright 2020, Royal Society of Chemistry.
Figure 7(A) Fabrication of PA-SAM functionalized Fe3O4 and CoFe2O4 MNPs. (B) Mechanisms of ROS generation under X-ray irradiation. (C) Determination of ROS concentration in MCF-7 cells. (D) Survival curves of MCF-7 cells incubated with functionalized CoFe2O4 MNPs. **P < 0.01, ****P < 0.001. Reproduced, with permission, from Klein et al. (2018). Copyright 2018, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Figure 8(A,B) Schematic illustration of fabrication and therapy mechanism of HOIL-PEG NSs. (C) ROS content of A549 cells after treated. (D) Morphology of representative tumors. (E) Tumor volume of A549 tumor-bearing nude mice after treatment. Statistical values are indicated in figures according to the following scale: *P < 0.05, **P < 0.01 and ***P < 0.001. Reproduced, with permission, from Ou et al. (2020). Copyright 2020, Elsevier.
Figure 9(A) Schematic illustration for FVIOs-GO-mediated MTD by combination of a heating effect and ROS-related immunologic effect. (B) Quantification of ROS generation of 4T1 breast cancer cells. (C) Quantification of M1 macrophages for treatments. (D) Tumor volume vs. days after treatments. *0.01 < P < 0.05;**0.001 < P < 0.01;***P < 0.001. Reproduced, with permission, from Liu et al. (2020). Copyright 2020, American Chemical Society.
Figure 10A schematic illustration for Fe3O4-Pd JNPs enhanced ROS-mediated antineoplastic therapy. Reproduced, with permission, from Ma et al. (2019). Copyright 2019, Royal Society of Chemistry.
Figure 11Schematic illustration for (A) preparation of polymersome nanoreactors and (B) cascade reactions in the nanoreactors. (C) Chemical structure of PEG-b-P(CPTKMA-co-PEMA). (D) Cascade reactions equations occurring in the nanoreactors. Reproduced, with permission, from Ke et al. (2019). Copyright 2019, American Chemical Society.
Figure 12(A) Schematic diagram of ISP-NMs and application for cancer treatment. (B) Fluorescent intensity of cancer cells after treatment. (C) Tumor volume changes during 14 days. *P < 0.05. **P < 0.01. ***P < 0.001 drugs treated groups versus one of control; #P < 0.05,P < 0.01,P < 0.001 other drugs treated groups versus the group of ISP-NMs+M. Reproduced, with permission, from Zhang et al. (2020a). Copyright 2020, Elsevier.
Figure 13(A) Schematic illustration of ferumoxytol-altered polarization of tumor-associated macrophages to release ROS, inducing cell death. (B) Signs of proinflammatory macrophage activation. (C) Quantitative measures of hydroxyl radical. (D) Coculture leads to increased caspase-3 expression of cancer cells. (E) Serial bioluminescence imaging after intravenous injection of ferumoxytol at a dose of 10 mg Fe kg−1. Reproduced, with permission, from Tarangelo and Dixon (2016) and Zanganeh et al. (2016). Copyright 2016, Macmillan Publishers Limited.
Summary of current ferrite nanoparticles used for ROS-mediated cancer therapy.
| Intrinsic fenton reaction | Fe3O4 (6, 13 nm) | Smaller size, higher enzyme activity | Zhang et al., |
| Fe3O4 (6, 9, and 14 nm) | Small size NPs destroy mitochondria, while larger size destroy cytomembrane | Xie et al., | |
| SPIONs (7.3, 15.1, 30.0 nm) | Zhang et al., | ||
| FeOx-MSNs | pH responsive, delivered to acidic lysosomes | Fu et al., | |
| Fe3O4 nanocluster, nanoflower, and nanodiamond | Fe3O4 nanodiamonds induce the highest cell killing effect | Fu et al., | |
| CuFe2O4 | Non-ferrous metal species regulate the ROS production | Ahamed et al., | |
| MB-CuFe NPs | Kuo et al., | ||
| SnFe2O4 | Lee et al., | ||
| Iridium oxide and iron oxide | Shaikh et al., | ||
| CuO, γFe2O3, CuZnFe2O3 | Siddiqui et al., | ||
| IONPA | Coating reduces nanoparticle size | Thoidingjam and Tiku, | |
| UC-IONP, CA-IONP, SP-IONP, AS-IONP, DA-IONP | Coatings decreases surface reactivity | Mai and Hilt, | |
| Fe2O3@DMSA, Fe2O3@APTS | DMSA-coating promotes uptake efficiency | Xie et al., | |
| Fe3O4/Fe@F-SiO2/PDA | Catalase-imprinted shell inhibits catalase activity to elevate H2O2 level | Chen et al., | |
| mag. SLPs | Targeting molecules, responsive molecules, improved delivery efficiency and selectivity | Swietek et al., | |
| Mito-PANPs | Pandey et al., | ||
| Fe5C2@Fe3O4 | Gradient core-shell structure, differential release | Yu et al., | |
| PEGylated FePt-Fe3O4 + doxorubicin | Combining ferrite nanoparticle and chemotherapeutic drugs, chemical and biological agents, etc. improves ROS-mediated tumor therapy. | Sahu et al., | |
| H2O2/Fe3O4-PLGA polymersome | Li et al., | ||
| Fe3O4 + (rapamycin or carboplatin) | Kojima et al., | ||
| DOX-ICG@Fe/FeO-PPP-FA nanocapsules | Wang et al., | ||
| TRAIL/Apo2L-iron oxide nanoparticles | Shi et al., | ||
| Thenmozhi, | |||
| Iron oxide nanoparticles | Broad applicability to a wide range of cancers: HepG2, A549, MCF-7, OVCAR-3, SKOV-3, HeLa S3, AGS, metastatic OC, OTSCC, etc. | Ahamed et al., | |
| Nickel ferrite nanoparticles | Ahamed et al., | ||
| Magnetite iron oxide nanoparticles | Gokduman, | ||
| Fe3O4@LEC-CUR-PLGA-MMS | Ayyanaar et al., | ||
| Fe3O4@CPTMOS/TP NPs | Habibzadeh et al., | ||
| α-Fe2O3 | Ramalingam et al., | ||
| SPIONs | Jahanbani et al., | ||
| SPIONs | Mechanisms: mitochondrial electron transport chain, antioxidant-related genes, mTOR-Akt-p70S6 K and ATG7, etc. | He et al., | |
| 9 nm Fe3O4 NPs | Ye et al., | ||
| PEI-MNPs | Man et al., | ||
| External field enhanced ROS | NiFe2O4/C | Enhanced by ultrasound | Gorgizadeh et al., |
| Citrate-coated SPIONs | Increased ROS production under X-ray irradiation, etc. | Klein et al., | |
| 9–20 nm (γ-Fe2O3)1− | Klein et al., | ||
| Cetuximab-IONPs | Bouras et al., | ||
| TAT-Fe3O4 | Hauser et al., | ||
| PA-SAM functionalized Fe3O4 and CoFe2O4 MNPs | Klein et al., | ||
| Zn2+-doped magnetic nanoparticles | Improved catalytic activity under NIR photothermal energy | Qi et al., | |
| Bacterial magnetic nanoparticles | Chen et al., | ||
| IONPs-ICG-HA | Wang et al., | ||
| γGDYO-Fe3O4-CREKA (TTIS) | Nanoplatform depolymerizes under NIR Photothermal energy | Min et al., | |
| Pt/Fe3O4@SP-PLGA | You et al., | ||
| FeTiO3@Fe2O3 | 650 nm laser irradiation formed photoexcited electron–hole | Ou et al., | |
| TAT-IONP | Improved catalytic activity under AMF magnetic heat | Hauser et al., | |
| Doxorubicin-loaded Fe3O4 nanoparticles | Orel et al., | ||
| mHAP | Yang et al., | ||
| Magnetic hydrogel nanozyme (MHZ) | Wu et al., | ||
| FVIOs-GO-CREKA | Liu et al., | ||
| Iron oxide magnetic nanoparticles | Magnetic heating superior to extrinsic hot air heating | Ludwig et al., | |
| Co0.2Mn0.8Fe2O4 | 0.5 T static magnetic field | Marycz et al., | |
| IONF@CuS | Synergistic effect of multi-field coupling (AMF and laser irradiation) | Curcio et al., | |
| Fe3O4-Pd | Ma et al., | ||
| Manganese doped-iron oxide nanoclusters (MNCs) | Gupta and Sharma, | ||
| Cascades increased ROS | SPION micelles | β-lapachone increases H2O2 | Huang et al., |
| LaCIONPs | Wang et al., | ||
| Fe3O4@C-FA | Ascorbic acid increases H2O2 | An et al., | |
| Vitamin C-conjugated Fe3O4 | Pal and Jana, | ||
| FePt-NP2 | Cisplatin activates NADPH oxidase to generate H2O2 | Ma et al., | |
| FeGd-HN@Pt@LF/RGD2 | Shen et al., | ||
| FA/Pt+si-GPX4@IONPs | Zhang et al., | ||
| GFD NCs | Glucose oxidase consumes glucose to generate H2O2 | Huo et al., | |
| Fe/G@R-NRs | Ke et al., | ||
| Fe3O4@PDA/GOx NPs | Zhang et al., | ||
| Nb2C-IO-CaO2 | CaO2 as H2O2 supplier | Gao et al., | |
| GO-FeOxH | Graphene oxide produces ROS under laser irradiation. | He et al., | |
| MFMSNs-Ce6 | Ferrite nanoparticles catalyze decomposition of H2O2 to O2 to overcome tumor hypoxia, improving ROS-mediated cancer therapy. | Kim et al., | |
| UCMnFe-PS-PEG | Ding et al., | ||
| MnFe2O4@MOF-PEG | Yin et al., | ||
| Copper ferrite nanospheres (CFNs) | Liu et al., | ||
| HP-HIONs | Zhang et al., | ||
| ISP-NMs | Zhang et al., | ||
| Ferumoxytol nanoparticles | Ferumoxytol acted on tumor-associated macrophages to adapt an antitumor “M1” phenotype, enhancing macrophage ROS production. | Zanganeh et al., | |
| Fe3O4-Au JNPs self-assembled vesicles | poly(lipid hydroperoxide) reacts with released Fe2+ to generate ROS | Song et al., |